Sugi Predict

Sugi Predict / Compounds / SCHEMBL505336

SCHEMBL505336

SCHEMBL505336

COC(=O)c1cc(Br)cc(N)c1N

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.49
▸ POLB P06746 1/20 0.49
▸ ALDH1A1 P00352 6/20 0.47
▸ GAA P10253 6/20 0.47
▸ HSD17B10 Q99714 4/20 0.47
▸ MAPT P10636 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ GLA P06280 2/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ CASP7 P55210 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ CFTR P13569 3/20 0.47
▸ ABL1 P00519 1/20 0.46
▸ TSHR P16473 2/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ NQO2 P16083 2/20 0.42
▸ NR4A2 P43354 1/20 0.41
▸ NOTUM Q6P988 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1115904 0.98 KDM4E (0.47) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL1119372 0.85 KDM4E (0.49) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL29562450 0.85 KDM4E (0.49) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL7413023 0.84 KDM4E (0.47) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL759268 0.84 KDM4E (0.47) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL24745625 0.84 KDM4E (0.47) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL12499964 0.84 KDM4E (0.47) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL29920315 0.84 KDM4E (0.47) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL16397204 0.82 KDM4E (0.46) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL16411013 0.82 KDM4E (0.46) KDM4EPOLBALDH1A1GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260097019-A1 METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS AURIGENE ONCOLOGY LTD (IN) 2026-04-09 — — US disclosed
US-12552757-B2 NRF2-activating compound SENJU PHARMACEUTICAL CO., LTD. (JP) 2026-02-17 — — US disclosed
US-20250213571-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2025-07-03 — — US disclosed
US-20250179017-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) 2025-06-05 — — US disclosed
US-12290507-B2 Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors AURIGENE ONCOLOGY LIMITED (IN) 2025-05-06 — — US disclosed
WO-2025059074-A1 BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2025-03-20 — — WO disclosed
CN-119487006-A Amide compounds as PGE2 receptor antagonists 广东新契生物医药科技有限公司 2025-02-18 — — CN disclosed
CN-119431323-A Heterobicyclic amides as CD38 inhibitors 贝林格尔·英格海姆国际有限公司 2025-02-14 — — CN disclosed
EP-4493562-A1 TYK2 INHIBITORS AND USES THEREOF Alumis Inc. (US) 2025-01-22 — — EP disclosed
EP-4482824-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS Guangdong Newopp Biopharmaceuticals Co., Ltd. (CN) 2025-01-01 — — EP disclosed
WO-2014128669-A2 TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-08-28 — — WO disclosed
WO-2014128669-A2 TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-08-28 — — WO disclosed
EP-2414328-A2 DIHYDROOROTATE DEHYDROGENASE INHIBITORS Merck Serono S.A. (CH) 2012-02-08 — — EP disclosed
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2012-02-02 — — US disclosed
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2012-02-02 — — US disclosed
EP-2281819-A1 Benzimidazolyl or benzoxazolyl derivatives Novartis AG (CH) 2011-02-09 — — EP disclosed
WO-2010115736-A2 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2010-10-14 — — WO disclosed
US-20090298824-A1 Organic compounds PRESS NEIL J 2009-12-03 — — US disclosed
EP-1709015-A1 ORGANIC COMPOUNDS Novartis AG (CH) 2006-10-11 — — EP disclosed
WO-2005070906-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2005-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179017-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS PTGER1, PTGER2, CNR2 KDM4E 2216/4885POLB 3555/4885ALDH1A1 940/4885
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS DHODH, FH, DPYD KDM4E 806/4885POLB 517/4885ALDH1A1 95/4885
US-20250213571-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK2 KDM4E 408/4885POLB 2979/4885ALDH1A1 4098/4885
US-12290507-B2 Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors DHODH, DHFR, DDO KDM4E 1677/4885POLB 1229/4885ALDH1A1 103/4885
US-12552757-B2 NRF2-activating compound NFE2L2, NFE2, KEAP1 KDM4E 1987/4885POLB 1619/4885ALDH1A1 790/4885
US-20260097019-A1 METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS MALT1, BRDT, BCL6 KDM4E 1851/4885POLB 1167/4885ALDH1A1 457/4885
US-20090298824-A1 Organic compounds CXCR2, CXCR3, CXCR1 KDM4E 4128/4885POLB 3284/4885ALDH1A1 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.